Alexion Pharmaceuticals (ALXN) Getting Somewhat Favorable Media Coverage, Study Finds

Press coverage about Alexion Pharmaceuticals (NASDAQ:ALXN) has been trending somewhat positive on Wednesday, Accern reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Alexion Pharmaceuticals earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.9577049685171 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:

Shares of Alexion Pharmaceuticals (ALXN) traded down $0.34 during mid-day trading on Wednesday, hitting $121.46. 1,434,357 shares of the stock were exchanged, compared to its average volume of 2,170,000. Alexion Pharmaceuticals has a 12-month low of $96.18 and a 12-month high of $149.34. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.51 and a current ratio of 2.96. The company has a market cap of $27,140.00, a P/E ratio of 54.22, a price-to-earnings-growth ratio of 1.03 and a beta of 1.17.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.32 by $0.12. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The firm had revenue of $859.00 million during the quarter, compared to the consensus estimate of $864.34 million. During the same quarter in the previous year, the firm posted $1.23 EPS. The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. sell-side analysts expect that Alexion Pharmaceuticals will post 4.82 earnings per share for the current fiscal year.

ALXN has been the subject of a number of recent analyst reports. TheStreet lowered shares of Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Friday, November 10th. BidaskClub upgraded shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, December 27th. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price objective for the company in a report on Tuesday, October 31st. Royal Bank of Canada initiated coverage on shares of Alexion Pharmaceuticals in a report on Thursday, September 14th. They issued an “outperform” rating and a $161.00 price objective for the company. Finally, Credit Suisse Group restated a “buy” rating and issued a $166.00 price objective on shares of Alexion Pharmaceuticals in a report on Tuesday, December 12th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and twenty have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $153.61.

In other news, CEO Ludwig Hantson sold 2,553 shares of the business’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total transaction of $310,521.39. Following the completion of the sale, the chief executive officer now owns 36,172 shares of the company’s stock, valued at approximately $4,399,600.36. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 4.35% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/10/alexion-pharmaceuticals-alxn-getting-somewhat-favorable-media-coverage-study-finds.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Insider Buying and Selling by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply